Caitong International Asset Management’s Protara Therapeutics TARA Stock Holding History

Caitong International Asset Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10	Buy	+2	New	+$12	﹤0.01%	2150

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Caitong International Asset Management's TARA Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Protara Therapeutics (TARA) in Q1 2026: 2 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #2150 among its holdings.

114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Caitong International Asset Management held 2 shares of Protara Therapeutics worth $10 as of Q1 2026.
Protara Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Protara Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2150 holding.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.